Could a fecal transplant help treat a rare liver disease?
NCT ID NCT06197308
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-stage trial is testing whether a transplant of healthy gut bacteria can be safely given to people with primary sclerosing cholangitis (PSC), a rare liver disease. Twenty-eight adults will first take antibiotics to clear their gut, then receive capsules containing freeze-dried bacteria. The goal is to see if the approach is safe and feasible, not yet whether it works.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- oral vancomycin, oral amoxicillin, and a freeze-dried microbiota preparation (MTP-101C)
- What this could lead to
- If it works, this could point toward a new way to manage primary sclerosing cholangitis by restoring gut bacteria balance.
- What could go wrong
- This is a very early, small pilot study (28 people) testing only safety and feasibility, not effectiveness. The treatment involves strong antibiotics and a live bacterial product, which may cause side effects or fail to show benefit.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PRIMARY SCLEROSING CHOLANGITIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
University of Minnesota
RECRUITINGMinneapolis, Minnesota, 55414, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new drug outperform standard care for a rare liver disease in teens?
- Could a new molecule tame a rare liver disease? early safety trial begins
- Blood test may tame the tightrope walk of transplant drugs
- Artificial intelligence may help decide who gets a liver first
- AI may outsmart current system for liver transplant priority
- Could a common drug stop a rare liver disease from returning after transplant?